BACKGROUND: The role of coronary microvascular disease and its impact on functional and energetic reserve in heart failure with preserved ejection fraction (HFpEF) remains unclear. We hypothesized that in response to submaximal pharmacologic stress (dobutamine), patients with HFpEF have impairment in left ventricular (LV) myocardial mechanical (external work [EW]), energetic (myocardial O2 consumption [MVO2]), and myocardial blood flow (MBF) reserve. We further assessed whether coupling of MBF to EW is impaired in HFpEF and associated with compensatory increases or pathological decreases in myocardial O2 extraction. Lastly, we assessed whether coupling of MVO2 to EW (mechanical efficiency) was impaired in HFpEF. METHODS AND RESULTS: In prospectively enrolled patients with HFpEF (n=19) and age/sex-matched healthy controls (n=19), we performed 11C-acetate positron emission tomography assessing MVO2 and MBF at rest and during dobutamine infusion. EW was calculated as stroke volume (echo)×end-systolic pressure×heart rate. At rest, compared with controls, patients with HFpEF had higher LV EW, MVO2, and MBF. With dobutamine, LV EW, MVO2, and MBF increased in both HFpEF and controls; however, the magnitude of increases was significantly smaller in HFpEF. In both groups, MBF increased in relation to EW, but in HFpEF, the slope of the relationship was significantly smaller than in controls. Myocardial O2 extraction was increased in HFpEF. Mechanical efficiency was similar in HFpEF and controls. In a post hoc analysis, HFpEF patients with LV hypertrophy (n=10) had significant reductions in LV mechanical efficiency relative to controls. CONCLUSIONS: In HFpEF during submaximal dobutamine stress, there is myocardial mechanical-, energetic- and flow-reserve dysfunction with impaired coupling of blood flow to demand and slight increases in myocardial O2 extraction. These findings provide evidence that coronary microvascular dysfunction is present in HFpEF, limits O2 supply relative to demand, and is associated with reserve dysfunction.
BACKGROUND: The role of coronary microvascular disease and its impact on functional and energetic reserve in heart failure with preserved ejection fraction (HFpEF) remains unclear. We hypothesized that in response to submaximal pharmacologic stress (dobutamine), patients with HFpEF have impairment in left ventricular (LV) myocardial mechanical (external work [EW]), energetic (myocardial O2 consumption [MVO2]), and myocardial blood flow (MBF) reserve. We further assessed whether coupling of MBF to EW is impaired in HFpEF and associated with compensatory increases or pathological decreases in myocardial O2 extraction. Lastly, we assessed whether coupling of MVO2 to EW (mechanical efficiency) was impaired in HFpEF. METHODS AND RESULTS: In prospectively enrolled patients with HFpEF (n=19) and age/sex-matched healthy controls (n=19), we performed 11C-acetate positron emission tomography assessing MVO2 and MBF at rest and during dobutamine infusion. EW was calculated as stroke volume (echo)×end-systolic pressure×heart rate. At rest, compared with controls, patients with HFpEF had higher LV EW, MVO2, and MBF. With dobutamine, LV EW, MVO2, and MBF increased in both HFpEF and controls; however, the magnitude of increases was significantly smaller in HFpEF. In both groups, MBF increased in relation to EW, but in HFpEF, the slope of the relationship was significantly smaller than in controls. Myocardial O2 extraction was increased in HFpEF. Mechanical efficiency was similar in HFpEF and controls. In a post hoc analysis, HFpEFpatients with LV hypertrophy (n=10) had significant reductions in LV mechanical efficiency relative to controls. CONCLUSIONS: In HFpEF during submaximal dobutaminestress, there is myocardial mechanical-, energetic- and flow-reserve dysfunction with impaired coupling of blood flow to demand and slight increases in myocardial O2 extraction. These findings provide evidence that coronary microvascular dysfunction is present in HFpEF, limits O2 supply relative to demand, and is associated with reserve dysfunction.
Authors: Kajenny Srivaratharajah; Thais Coutinho; Robert deKemp; Peter Liu; Haissam Haddad; Ellamae Stadnick; Ross A Davies; Sharon Chih; Girish Dwivedi; Ann Guo; George A Wells; Jordan Bernick; Robert Beanlands; Lisa M Mielniczuk Journal: Circ Heart Fail Date: 2016-07 Impact factor: 8.790
Authors: Ilkka Heinonen; Nobuyuki Kudomi; Jukka Kemppainen; Antti Kiviniemi; Tommi Noponen; Matti Luotolahti; Pauliina Luoto; Vesa Oikonen; Hannu T Sipilä; Jaakko Kopra; Ilkka Mononen; Dirk J Duncker; Juhani Knuuti; Kari K Kalliokoski Journal: Basic Res Cardiol Date: 2014-05-28 Impact factor: 17.165
Authors: Paul S Bhella; Anand Prasad; Katja Heinicke; Jeff L Hastings; Armin Arbab-Zadeh; Beverley Adams-Huet; Eric L Pacini; Shigeki Shibata; M Dean Palmer; Bradley R Newcomer; Benjamin D Levine Journal: Eur J Heart Fail Date: 2011-10-05 Impact factor: 15.534
Authors: Barry A Borlaug; Wissam A Jaber; Steve R Ommen; Carolyn S P Lam; Margaret M Redfield; Rick A Nishimura Journal: Heart Date: 2011-04-08 Impact factor: 5.994
Authors: Muaz M Abudiab; Margaret M Redfield; Vojtech Melenovsky; Thomas P Olson; David A Kass; Bruce D Johnson; Barry A Borlaug Journal: Eur J Heart Fail Date: 2013-02-20 Impact factor: 15.534
Authors: R S Beanlands; D S Bach; R Raylman; W F Armstrong; V Wilson; M Montieth; C K Moore; E Bates; M Schwaiger Journal: J Am Coll Cardiol Date: 1993-11-01 Impact factor: 24.094
Authors: Pasquale Paolisso; Emanuele Gallinoro; Niya Mileva; Ana Moya; Davide Fabbricatore; Giuseppe Esposito; Cristina De Colle; Monika Beles; Jerrold Spapen; Ward Heggermont; Carlos Collet; Guy Van Camp; Marc Vanderheyden; Emanuele Barbato; Jozef Bartunek; Martin Penicka Journal: ESC Heart Fail Date: 2021-11-24
Authors: Jerremy Weerts; Sanne G J Mourmans; Arantxa Barandiarán Aizpurua; Blanche L M Schroen; Christian Knackstedt; Etto Eringa; Alfons J H M Houben; Vanessa P M van Empel Journal: Biomolecules Date: 2022-02-09